A Novel Role for CSRP1 in a Lebanese Family with Congenital Cardiac Defects by Kamar, Amina et al.
A Novel Role for CSRP1 in a Lebanese
Family with Congenital Cardiac Defects
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Kamar, A., A. C. Fahed, K. Shibbani, N. El-Hachem, S. Bou-Slaiman,
M. Arabi, M. Kurban, et al. 2017. “A Novel Role for CSRP1 in a
Lebanese Family with Congenital Cardiac Defects.” Frontiers
in Genetics 8 (1): 217. doi:10.3389/fgene.2017.00217. http://
dx.doi.org/10.3389/fgene.2017.00217.
Published Version doi:10.3389/fgene.2017.00217
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:34868978
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
ORIGINAL RESEARCH
published: 18 December 2017
doi: 10.3389/fgene.2017.00217
Frontiers in Genetics | www.frontiersin.org 1 December 2017 | Volume 8 | Article 217
Edited by:
Enrico Baruffini,
Università degli Studi di Parma, Italy
Reviewed by:
Cecilia Vecoli,
Consiglio Nazionale Delle Ricerche
(CNR), Italy
Christoph Sinning,
Universitäts-Herzzentrum Freiburg,
Germany
*Correspondence:
Elias Baydoun
eliasbay@aub.edu.lb
Georges Nemer
georges.nemer@aub.edu.lb
Specialty section:
This article was submitted to
Genetic Disorders,
a section of the journal
Frontiers in Genetics
Received: 19 October 2017
Accepted: 04 December 2017
Published: 18 December 2017
Citation:
Kamar A, Fahed AC, Shibbani K,
El-Hachem N, Bou-Slaiman S,
Arabi M, Kurban M, Seidman JG,
Seidman CE, Haidar R, Baydoun E,
Nemer G and Bitar F (2017) A Novel
Role for CSRP1 in a Lebanese Family
with Congenital Cardiac Defects.
Front. Genet. 8:217.
doi: 10.3389/fgene.2017.00217
A Novel Role for CSRP1 in a
Lebanese Family with Congenital
Cardiac Defects
Amina Kamar 1, Akl C. Fahed 2, 3, 4, Kamel Shibbani 5, Nehme El-Hachem 6,
Salim Bou-Slaiman 5, Mariam Arabi 7, Mazen Kurban 5, 8, 9, Jonathan G. Seidman 2,
Christine E. Seidman 2, 4, Rachid Haidar 10, Elias Baydoun 1*, Georges Nemer 3* and
Fadi Bitar 7
1Department of Biology, American University of Beirut, Beirut, Lebanon, 2Department of Genetics, Harvard Medical School,
Boston, MA, United States, 3Department of Medicine, Massachusetts General Hospital, Boston, MA, United States,
4Division of Cardiology, Howard Hughes Medical Institute, Brigham and Women’s Hospital, Boston, MA, United States,
5Department of Biochemistry and Molecular Genetics, American University of Beirut, Beirut, Lebanon, 6 Faculty of Medicine,
McGill University, Montreal, QC, Canada, 7Department of Pediatrics and Adolescent Medicine, American University of Beirut,
Beirut, Lebanon, 8Department of Dermatology, American University of Beirut, Beirut, Lebanon, 9Department of Dermatology,
Columbia University, New York, NY, United States, 10Department of Surgery, American University of Beirut, Beirut, Lebanon
Despite an obvious role for consanguinity in congenital heart disease (CHD), most studies
fail to document a monogenic model of inheritance except for few cases. We hereby
describe a first-degree cousins consanguineous Lebanese family with 7 conceived
children: 2 died in utero of unknown causes, 3 have CHD, and 4 have polydactyly.
The aim of the study is to unveil the genetic variant(s) causing these phenotypes using
next generation sequencing (NGS) technology. Targeted exome sequencing identified
a heterozygous duplication in CSRP1 which leads to a potential frameshift mutation at
position 154 of the protein. This mutation is inherited from the father, and segregates only
with the CHD phenotype. The in vitro characterization demonstrates that the mutation
dramatically abrogates its transcriptional activity over cardiac promoters like NPPA. In
addition, it differentially inhibits the physical association of CSRP1 with SRF, GATA4, and
with the newly described partner herein TBX5. Whole exome sequencing failed to show
any potential variant linked to polydactyly, but revealed a novel missense mutation in
TRPS1. This mutation is inherited from the healthy mother, and segregating only with
the cardiac phenotype. Both TRPS1 and CSRP1 physically interact, and the mutations
in each abrogate their partnership. Our findings add fundamental knowledge into the
molecular basis of CHD, and propose the di-genic model of inheritance as responsible for
such malformations.
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INTRODUCTION
Congenital heart defects arise during pregnancy, and are subsequently the most prevalent birth
defects worldwide (Hoffman and Kaplan, 2002). They affect chamber and valve formation and
function leading to different phenotypes referred to as Congenital Heart Disease (CHD), the
major cause of neonatal morbidity and mortality in humans. CHD accounts for one third
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of all main congenital defects with variable prevalence crosswise
countries. In Lebanon, the incidence of infants born with CHD
between 1980 and 1995 was 11.5 per 1,000 live births (Bitar
et al., 1999), and twenty per cent of those patients were found
to be from first degree cousin mating (Nabulsi et al., 2003).
Although many studies have attempted to establish a relationship
between CHD and consanguinity, the significance of this
association and its precise nature is still unclear. So far, at least 50
human disease genes have been associated with CHD, however,
a small set of developmental genes [for example, NKX2-5
(MIM# 600584), GATA4 (MIM# 600576) and NOTCH1]
harbor the majority of these CHD-associated mutations
(Fahed et al., 2013).
Mutations in genes encoding LIM domain proteins have
been however, rarely associated to cardiac morphogenesis or
CHD. The LIM domain contains a conserved double zinc finger
motif that is evolutionary conserved and is found in a variety
of proteins displaying distinct biological roles (Schmeichel and
Beckerle, 1994). The LIM domains have been observed to act
as a mediator of protein-protein interactions in the cytoplasm
and the nucleus. These interactions with specific protein partners
are now known to influence its subcellular localization and
activity (Khurana et al., 2002; Kadrmas and Beckerle, 2004;
Camarata et al., 2006). Many LIM proteins that were initially
identified as cytoskeleton-associated proteins, such as members
of the cysteine-rich protein (CRP) families, four-and-a-half LIM
(FHL), PINCH and Zyxin are recognized to shuttle between the
cytoplasm and nucleus of the cell to influence gene expression
(Sadler et al., 1992; Schmeichel and Beckerle, 1994; Bianchi-
Smiraglia et al., 2013). This dual localization is due to the
presence of a putative nuclear targeting signal (KKYGPK) that
has been identified in the glycine-rich regions of the CRPs. In
humans, three CRP-family members (group two of LIM domain
proteins) have been identified which are: CSRP1 (MIM# 123876),
CSRP2, and CSRP3/MLP (Pomiès et al., 1997; Henderson et al.,
2002;Weiskirchen andGunther, 2003). CSRPs are small proteins,
22 kDa in size, and contain two functional LIM domains that
are linked to glycine-rich repeat. CSRP family members play a
role in terminal differentiation in vertebratemuscle development.
CSRP1 andCSRP2 are prominent in smoothmuscle while CSRP3
is expressed in striated muscle (Weiskirchen and Gunther, 2003).
In embryonic development CSRP1 participates in the formation
of heart, and its downregulation alters cardiac-committed
mesodermal cell migration resulting in cardia bifida in zebrafish
(Miyasaka et al., 2007). CSRP1 inhibition leads to irregular
cell movement in convergent extension resulting in anomalies
in midline structures. In adult mouse, CSRP1 is expressed in
the smooth muscle cells of cardiac arteries. CSRP1 and CSRP2
were shown to function through coordinated docking of Serum-
Response Factor (SRF) to the N-terminal LIM domain and
GATA factors, specifically GATA4 and GATA6, to the C-terminal
LIM domain (Lilly et al., 2001, 2010). The strong expression of
many smooth muscle-differentiation markers is stimulated by
this ternary complex of SRF–CSRP–GATA, whereas the pairwise
combinations have much less impact on gene expression. In the
cytoplasm, CSRPs that are associated with the actin cytoskeleton
might function as sensors to assess the physiological status of
the contractile machinery by interacting with α-actinin, and with
the adhesion plaque LIM protein domain Zyxin (Sadler et al.,
1992).
The interaction of CSRP proteins with GATA zinc finger
transcription factors underscores their potential implication in
CHD, since mutations in genes encoding all three cardiac
enriched GATA proteins were shown to be associated with
multiple forms of structural cardiac defects (Kassab et al., 2016
#3679; Nemer et al., 2006 #44). Besides GATA4, 5, and 6, an
atypical GATA protein was shown to bind the specific GATA
sequence on DNA and competes with the canonical GATA
proteins to repress their activities (Momeni et al., 2000; Malik
et al., 2001; Kunath et al., 2002). Besides GATA1-6, few proteins
harbor a GATA-zinc finger motif in their structure. Amongst
these, TRPS1 (Trichorhinophalangeal syndrome type I) contains
nine putative zinc finger domains with the seventh finger
representing the GATA-type while zinc fingers 8 and 9 reveal
homology to a conserved domain of lymphoid transcription
factors that belong to Ikaros family (Momeni et al., 2000; Malik
et al., 2001). TRPS1 differs from other GATA proteins by its
in vitro and in vivo activity as a sequence-specific transcriptional
repressor rather than an activator since although it binds
a GATA sequence, it fails to activate GATA transactivation
reporter (Malik et al., 2001). Mutations in the TRPS1 (MIM#
604386) is linked to the autosomal dominantly inherited
TRP (tricho-rhino-phalangeal) syndrome which is characterized
by skeletal and craniofacial malformations (Momeni et al.,
2000; Kunath et al., 2002). Specifically, some of the major
features include hip malformations, sparse scalp hair, bulbous
tip of the nose, protruding ears, short stature, brachydactyly,
and cone-shaped epiphyses in the phalanges (Momeni et al.,
2000; Malik et al., 2001). Recent studies have shown that
some patients with this syndrome display wide range of
congenital cardiac defects including persistent foramen ovale
(PFO), persistent ductus arteriosus (PDA), aortic stenosis, and
left cardiac insufficiency (Verheij et al., 2009; Maas et al.,
2015).
We have recently identified a large Lebanese family with
CHD and polydactyly composed of the consanguineous
marriage between two first-degree cousins. Out of the 7
conceived children, 2 died in utero at the ages of 6 and 9
months of unknown causes. Of the remaining 5 children,
3 have CHD (ventricular septal defect, atrial septal defect,
and patent ductus arteriosus), and 4 have polydactyly (2
have both). We thus carried targeted and subsequently
whole exome sequencing to unravel the genotype-phenotype
relationship within this family. The targeted sequencing of 119
cardiac candidate genes, led to the identification of a novel
heterozygous frameshift variant in CSRP1 in all probands
with cardiac defects. This variant is inherited from the
unaffected father. Whole exome sequencing showed amongst
other a potentially damaging missense varaint in TRPS1
inherited from the unaffected mother. We aimed thus to
study the effect of these variants on the protein function and
structure in vitro, and our results suggest a digenic model of
inheritance that would explain the occurrence of CHD in this
family.
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MATERIALS AND METHODS
Patient Recruitment and Clinical
Examination
The study was approved by the institutional review board
(IRB) at the American University of Beirut (protocol number:
Bioch.GN.01). All subjects gave written informed consent in
accordance with the Declaration of Helsinki. Children and
adolescents under age of 16 signed an assent form, and got
their parents’s written consents to be included in the study.
Genetic analyses and return of genetic data were performed in
accordance with protocols approved by the Partners Human
Research Committee. A total of 20 individuals from the same
family were enrolled. Standard clinical evaluation included a
comprehensive physical exam, electrocardiography (ECG), and
two-dimensional (2D) transthoracic echocardiography (TTE)
with color Doppler. All affectedmembers underwent karyotyping
to assess chromosomal integrity.
Genetic Analysis
Peripheral venous blood was collected from all family members,
and DNA extraction was performed using the Qiagen Blood-
Midi kit (Qiagen Science Inc., Germantown, MD, USA),
following the manufacturer’s protocol. DNA quantification was
performed using the NanoDrop (Thermo Fisher Scientific
Inc., Waltham, MA, USA) at the molecular core facility at
AUB. Targeted DNA sequencing was done at Harvard as
previously described. One microgram of coded DNA samples
from both parents, the proband, four of her siblings, and
three of her cousins were shipped to Macrogen, South Korea
(http://dna.macrogen.com/eng/) where exome sequencing was
performed. Briefly, the samples were prepared according to
an Agilent V6 SureSelect Target Enrichment Kit preparation
guide. The SureSelect Target Enrichment workflow is solution-
based system utilizing ultra-long—120 mer biotinylated cRNA
baits—to capture regions of interest, enriching them out
of a NGS genomic fragment library (Chen et al., 2015;
#2881).The libraries were sequenced with an IlluminaHiSeq 2000
sequencer. The Illumina technology utilizes a unique “bridged”
amplification reaction that occurs on the surface of the flow cell.
Sequencing-by-Synthesis utilizes four proprietary nucleotides
possessing reversible fluorophore and termination properties
(Bentley et al., 2008; #2882).
Primary analysis was done at Macrogen. Generated Fastq files
were mapped to the reference genome using the Burros-Wheeler
Alignment Tool (BWA), and the Genome Analysis Toolkit
(GATK) was used for variants call, while the SnEff software was
used to annotate the variants. Variant analysis was done using
the Illumina variant call software, using a family based approach
and comparing results to an in house 200 exomes database
and to the available online exome and genome databases.
Variants segregating with the phenotype (s) were submitted to
the Leiden Operation Variome Database (http://www.lovd.nl/
3.0/home) under screening ID# 00121860. Sanger sequencing
was used to confirm the genotype of the CSRP1 and TRPS1
variants in all available family members. Briefly, amplification by
polymerase chain reaction (PCR) was done using the Phusion
polymerase high-fidelity master mix (F-548S) on a Pico machine
(Finnzymes, Espo, Finland), and the amplicons were resolved
on a 1.5% agarose gel. Gel purification was performed using
the Gel Extraction kit following the manufacturer’s protocol
(peqGOLD Gel Extraction Kit, PeqLab, Erlangen, Germany).
The purified bands were quantified using a NanoDrop (Thermo
Fisher Scientific Inc., Waltham, MA) and examined by gel
electrophoresis to ensure quality. DNA sequencing was carried
out on an ABI 3500 machine at the molecular core facility at
the American University of Beirut, followed by analysis using
the data collection software fromApplied Biosystems Inc. (Foster
City, CA).
Detection of Copy Number Variants from
WES
Read counts for all exons were extracted from clinical samples,
following the computational approach proposed by Zhang et al.
(2015). Briefly, the GRch38 version of the Human genome and
a target region covering 50MB of exons is used to extract
counts from BAM (Binary alignment map) files for patients and
controls, respectively. The resulting compressed ∗tar.gz file is
then submitted to the DeAnnCNV webserver which infers the
CNV for each subject based on a previously described algorithm:
the Global Parameter Hidden Markov Model (GPHMM) (Li
et al., 2011). DeAnnCNV identifies a shared CNV pattern
between patients and provides further annotation of the genes
associated with these CNVs.
Cell Lines and Plasmids
HEK293 cells (Human Embryonic Kidney cells) and Hela cells
(Human cervical cancer cells) were cultured and maintained in
Dulbecco’s Modified Eagle Media (DMEM-Sigma, Cat#D0819)
supplemented with 10% Fetal Bovine Serum (FBS-Sigma,
Cat#F9665), 1% Penicillin/ Streptomycin (Biowest-Cat#L0022-
100) and 1% sodium pyruvate (Sigma-Cat#S8636). Incubation of
cells was carried out in a 5% CO2 humid atmosphere at 37
◦C.
Luciferase reporter plasmids PGL3-VEGF-luc, PGL2-NOS3-
luc, and PXP2-NPPA-luc were constructed by ligation of PCR–
amplified fragments from mouse VEGF, human NOS3 and rat
NPPA promoters into eukaryotic luciferase expression vectors
PGL3, PGL2, and pXP2 respectively. pCGN-HA-SRF, HA-
tagged pCGN-GATA (4, 5, and 6) and pCGN-TBX5 were
cloned into eukaryotic expression vector pCGN. pCMV3-
HA-TRSP1 was from Sino Biological Inc. (Cat# HG15989-
NY). Flag-tagged wild type human CSRP1 was generated by
subcloning CSRP1 fragments into expression vector pCEP4
(Invitrogen). Flag-tagged p.E154Vfs∗99 CSRP1 mutant was
constructed through site-directed mutagenesis in which PCR
amplified fragments harboring the p.E154Vfs∗99 mutation were
ligated into eukaryotic expression vector pCEP4. Site directed
mutagenesis was also carried out to introduce p.R311S TRPS1
mutation into the wild-type (WT) TRPS1. After the ligation of the
resulting amplicons, transformation into XL-1 Blue competent
bacteria was performed. Finally, the yielded plasmids were
extracted and sequenced thereafter in order to confirm the
incorporation of the mutations.
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Antibodies
Rabbit polyclonal antibody to CSRP1 Cat#:ab70010; Goat
anti-mouse antibodies (HRP) Cat# ab6789; and goat anti-
rabbit antibodies (HRP) Cat# ab97051 were purchased from
Abcam. Mouse monoclonal antibody against flag-tag (OCTA-
probe H-5) Cat# sc-166355 and rabbit polyclonal antibodies
against HA-tag (HA-probe Y-11) Cat# sc-805 were from Santa
Cruz. Mouse Biotinylated species-specific whole antibody (from
donkey), Cat#: LRPN1001V and rabbit biotinylated species-
specific whole antibody (from sheep); Cat# RPN1004V were
from GE healthcare UK limited. Streptavidin Red full length
Cat#ab136227 was from abcam. Goat anti-rabbit Alexa fluor 488
was from Invitrogen Cat#A11008.
Transfection Assays to Assess CSRP1
Target Gene Promoters
HEK293 cells were grown and maintained at subconfluence
∼60% level in Dulbecco’s modified Eagle’s Medium (DMEM-
Sigma) containing 10% fetal bovine serum (FBS). Transient
transfections were performed with Polyethylenimine (Sigma).
A series of Luciferase assays were performed by transient
transfection in combination with pCEP4-Flag-WTCSRP1,
pCEP4-Flag-p. E154Vfs∗99 CSRP1,PCGN-HA-SRF,pCGN-HA-
GATA4, pCGN-HA-GATA4,luciferase reporters (3.5 µg) and
empty expression vectors, PCGN, to a balanced total of 1 µg
of plasmids per 2 wells of the 12-well plate. The results were
normalized the total protein concentration in each well, and
were expressed as fold activation. Cotransfection experiments
were performed in duplicates and repeated at least three
times. Luciferase activity was normalized to baseline reporter
gene activity as fold activation, with error bars representing
SEM.
Protein Overexpression and Western
Blotting
HEK293 cells were transiently transfected with epitope-
tagged vectors pCGN-HA-GATA4, pCEP4-Flag-WTCSRP1,
pCEP4-Flag-p.E154Vfs∗99 CSRP1, pCEP4-HA-TBX5,
pCGN-HA-GATA5, pCGN-HA-GATA6, PCGN-HA-SRF,
pCMV3-HA-TRSP1, and pCMV3-HA-p.R311S TRPS1 using
Polyethylenimine (Sigma). HEK293 cells were plated in 100mm
corning culture plates until subconfluence ∼80% determined
by green fluorescent protein (GFP) transfection assay. After
24 h, 20 µg of DNA and 35 µl PEI (transfection reagent) were
added to an Eppendorf tube holding a total volume of 1ml
DMEMmedium. The mixture was vortexed for 10 sec, incubated
20min at RT, and then applied over the cells. Culture medium
was changed after 3 h of transfection. Nuclear extracts from
transfected HEK293 cells were obtained as previously described.
For immunoblotting, 10 µg of nuclear extracted proteins were
mixed with 5X Laemmli Buffer. The protein samples were
boiled for 5min and run on denaturing SDS-PAGE for about
1.5 h then transferred to a PVDF membrane (Amersham,
UK) Cat#10600023. The membrane was blocked in 5%TBT
(TBS-0.02% Tween 20) skimmed dry milk for 45min at RT. The
membrane was incubated with primary antibodies, anti-Flag
or ant-HA (1:1,000) overnight at 4◦C. On the second day, the
membrane was washed three times with TBT and incubated
with secondary anti-mouse or anti-rabbit-HRP (1:50,000)
for 1 h at RT. Development was done using ECLTM Western
Blotting Detection Reagents (Amersham, GE healthcare, Cat#
RPN2106). The protein bands were visualized by Chemidoc
MP imaging systemBio-Rad and quantified using Image J
software.
Co-immunoprecipitation
After detecting WT CSRP1, p.E154Vfs∗99 CSRP1, GATA-4, -5,
and -6, SRF, TBX5, and WT TRPS1 and p.R311S TRPS1 proteins
by western blot, co-immunoprecipitation assay was done to
assess the physical interaction between WT/ p.E154Vfs∗99
CSRP1 (Flag-tagged), GATA-4, -5, and -6 (HA-tagged), SRF (HA-
tagged), TBX5 (HA-tagged), and WT/p.R2311S TRPS1 (HA-
tagged). About 5 µg of anti-rabbit HA (Santa Cruz) plus
PBS (1x, 0.001% Tween 20) were incubated with Dynabeads R©
Protein G [size: 1ml (30mg/ml) Novex by Life Technologies,
Cat# 10003D] for 1 h at 4◦C. 200 µg of total proteins
(ten times the amount used in western blot) were incubated
with antibodies and beads for 2 h at RT. Immunocomplexes
were captured on magnet and washed three times with
PBS 1X. Coimmunoprecipitated proteins were subjected to
Western Immunoblot analysis as per regular protocol (anti-Flag,
1:1,000). PVDF membrane was stripped and probed with anti-
HA antibody (Santa Cruz), 1:1,000. The protein bands were
visualized by autoradiography.
Immunostaining
Hela cells were grown onto 12-well costar culture plates on
coverslips at subconfluence ∼60% level and maintained in
Dulbecco’s modified Eagle’s medium (DMEM) having 10%
FBS. Transfections were done using polyethylenimine (PEI-
Sigma). Five micrograms of DNA was diluted in 150 µl of
serum free DMEM medium and 6 µl of PEI was added
into an Eppendorf in a ratio of 1:3 DNA to PEI. Hela
cells were fixed in 4% paraformaldehyde (Hummel et al.,
1990). Nonspecific binding was blocked with 3% Bovine serum
Albumin (BSA) in 0.2% PBS-Tween20 (PBT) and primary mouse
monoclonal antibody (1:250) against flag-tag (OCTA-probe H-5)
or rabbit polyclonal IgG (HA-probe Y-11) were applied overnight
at 4◦C. Secondary anti-mouse Biotinylated species-specific
whole antibody (from donkey), GE healthcare UK limited,
or secondary anti-Rabbit biotinylated species-specific whole
antibody (from sheep); diluted 1:500 was added for 1 hour
at room temperature. Cells were washed three times with
PBT and incubated for 1 hour at room temperature with
Streptavidin Texas Red full length (abcam, Cat#ab136227)
diluted 1:500. Cells were washed three times with PBT and
incubated with Hoechst staining for the nucleus, diluted 1:30
in water, for 15 minutes. The cells were then mounted on
a rectangular slide containing an anti-fading agent DABCO
(Sigma-Aldrich). The slides were examined using the Olympus
BH-2 microscope at the molecular core facility in the faculty of
medicine-AUB.
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Immunohistochemistry
Continuous sections which are 5µm thick were prepared
from each formalin-fixed, paraffin embedded tissue.
Immunohistochemical staining was performed to evaluate
the expression of CSRP1. All sections on the slides were
dewaxed and rehydrated with xylene and graded alcohol, then
dripped 3% hydrogen peroxide on them to quench endogenous
peroxidase. Afterwards, high-temperature antigen retrieval
was carried out in citrate buffer (pH 6.0) in a microwave
oven to enhance immunoreactivity, followed by 3% BSA
(Amresco Life science, Cat#0332-100G) in 0.2% PBT to
reduce the non-specific bindings. Primary rabbit-antibody
against CSRP1 (ab70010, abcam, 1:100) were applied to
the sections respectively and incubated overnight at 4◦C.
Subsequently, slides were incubated with 1:250 secondary
anti-rabbit Biotinylated species-specific whole antibody (from
donkey), (GE healthcare UK limited, Cat# RPN1004V) and
1:250 streptavidin–peroxidase conjugate, and antibody-
specific binding was visualized with 3,3-diaminobenzidine
solution (DAB –Sigma, Cat#D3939-1SET). Lastly, slides were
counterstained with Methyl Green and mounted. PBS was used
as a negative control by replacement of the relevant primary
antibody.
Statistical Analysis
The significance of luciferase assay was studied using Paired
Students’ T-test. The results are presented as fold activation
and the values are Mean ± SD (standard deviation). Each
experiment was performed in duplicates and repeated three
times (n = 3). The significance is defined as ∗p < 0.05 or
∗∗p < 0.01.
RESULTS
A CHD consanguineous multiplex family with CHD and
polydactyly was recruited as part of the Congenital Heart
Disease Genetics Program at the American University of Beirut
(Figure 1). The indexed-patient (III-8, Figure 1) presented
to the AUB-MC Children’s Heart center shortly after birth
with a patent ductus arteriosus (PDA) and bilateral postaxial
polydactyly on both hands and feet: the PDA was closed using
an AmplatzerTM device. The girl passed away at 7 years of
age following a severe lung infection. Her brother (III-10)
presented with a small perimembraneous ventricular septal
defect (VSD), lower extremity bilateral postaxial polydactyly,
right hand syndactyly with postaxial finger formation, and
left hand postaxial polydactyly with syndactyly in the 4th and
5th digits. Further examination of the core family (Figure 1)
showed that the father (II-8) has bilateral postaxial polydactyly
on feet and hands while the mother (II-9) is phenotypically
normal (Figure 1). Both parents and the unaffected child
(III-9) were confirmed upon echocardiography to be CHD
free. The parents are first degree cousins, and had recently
monozygotic twin-girls; one of them with a patent foramen
ovale (PFO) and left-hand postaxial polydactyly (III-11), while
the other (III-12) has only an atrial septal defect (ASD)
(Figure 1).
CHD Targeted Sequencing: The CSRP1
Variant
Targeted sequencing of 119 genes implicated in CHD for
probands III-8 and III-10 showed that none of these genes
harbor shared rare (MAF < 1%) damaging variants except
for the CSRP1 gene (Supplementary Table 1). The variant
[NM_004078.2:c.447_460dupTGGCAAAGGCCTTG] is an
insertion of a segment of 14 nucleotides chr1:20145445-
T>TCAAGGCCTTTGCCA that leads to a frameshift mutation
with an extended C-terminal domain of the protein p.E154Vfs∗99
(Figure 2A). The variant was shared by both probands and
was neither present in the Genome Aggregation Database
(gnomAD), nor in 200 Lebanese patients with CHD screened
using the same approach. The variant was confirmed by Sanger
sequencing (Figure 2B). Genotype-phenotype analysis across
the extended pedigree did not support any role for CSRP1 in
the polydactyly phenotype, but suggested a potential role in
the cardiac phenotype observed in the core family since the
third affected child with ASD III-12 carried the variant, whereas
proband III-9 who has no cardiac phenotypes did not (Table 1).
The variant is inherited from the father who has a normal heart
on echocardiography. This suggested that this variant could
be involved in the cardiac phenotype observed in the family.
Indeed, we carried out a Barnard’s test for 2 × 2 contingency
table and it showed a p-value of 0.021. This was corroborated by
a Fisher’s exact test yielding a p-value of 0.0476; both suggesting
a significant association of the CSRP1 variant with the CHD
phenotype.
We thus, retrieved the coding sequence of the human CSRP1.
Our analysis indicates that the duplication of 14 nucleotides in
exon 5 (Figure 2A) leads to a reading frameshift that disrupts
the 2nd LIM domain and extends the C-terminal domain of
the protein (NP_001180500) (Figure 2C). The mutated protein
harbors 253 amino acids instead of 193 suggesting a potential
conformational, structural, and functional change.
Cardiac Expression and Cellular
Localization of CSRP1
Before characterizing the impact of the mutation on the protein
cellular localization and transcriptional activity, we did look
at the expression of the protein during heart development in
mice to correlate it with the phenotype(s) observed in the
affected individuals. Results of immuno-staining showed a strong
expression of the protein in the heart at all stages of development
starting as early as E12.5, and onwards with a strong nuclear
expression in all cardiac compartments, but not in the valves
(Supplementary Figure 1). Of note the absence of the expression
of the protein in the endocardial cells, and the progressive
increase in the cytoplasmic localization of the protein whereby
the newborn hearts of mice have mainly cytoplasmic CSRP1.
Characterization of the Transcriptional
Activity of the CSRP1 Mutated Protein
In order to assess the impact of the p.E154Vfs∗99 mutation
on the structural and functional properties of CSRP1, site-
directed mutagenesis was carried out on the coding region
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FIGURE 1 | Congenital heart and limb deformities in a large consanguineous Lebanese family. The pedigree shows a three generations’ family (roman numbers) with
inherited polydactyly (gray symbols) or congenital heart defects amongst its members (Arabic numbers). Red and green dotted lines indicate first and second degree
cousin marriages respectively.
FIGURE 2 | The CSRP1 variant alters the structure of the protein. (A) Integrative genomics viewer (IGV) visualization of the targeted exome sequencing shows an
insertion (Blue line) in Csrp1 gene. (B) Sanger Sequencing of the CSRP1 gene confirmed the 14 nucleotides duplication (TGTGGCAAAGGCCT) in exon 5.
(C) Schematic representation of the mutation that abrogates the second LIM domain of the protein.
of the human CSRP1 cDNA subcloned into a Flag-tagged
plasmid. Both plasmids were sequenced before transiently
expressing them into Hela and HEK293 cells. The wild type and
mutated proteins were equally produced as assessed by western
blot analysis of nuclear proteins extracted from these cells
(Supplementary Figure 2A). Cellular localization was assessed in
Hela cells which showed that both the wild type and mutated
proteins are present in both the nuclei and cytoplasm of the
transfected cells with no substantial differences (Supplementary
Figure 2B).
Although CSRP1 is predicted to act as a transcription factor,
no previous studies have shown a direct activity of this protein
on promoter regions of genes. In order to assess the effect of
p.E154Vfs∗99 mutation on the function of CSRP1, HEK293 cells
were transiently transfected with increasing concentrations of the
plasmid encoding either the wild type or mutant CSRP1 along
with a fixed dose of either one of the following cardiac and/or
vascular enriched promoters fused to Luciferase: NPPA, VEGF,
and NOS3. While the wild type protein was able to activate the
promoters in a dose-dependent manner reaching up to 6-fold
over the NOS3 promoter, the mutation completely abolished this
activity (Figure 3).
The weak transactivation properties of the CSRP1 protein
coupled to the lack of a bona fide binding site for this class of
LIM proteins prompted us to look at the effect of the mutation
on its interacting partners.
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The p.E154Vfs∗99 Mutation Alters the
Physical and Functional Interaction
between CSRP1 and SRF
CRSP1 was previously shown to be recruited preferentially by
the serum response factor (SRF) protein to promoter regions
of target genes involved in smooth muscle cells differentiation
(Chang et al., 2003). We thus assessed the effect of the
mutation on this interaction by co-immunoprecipitation assays
TABLE 1 | Genotype of Family Members for CSRP1 and TRPS1 variants.
Family member CSRP1 (p.E154Vfs*99) TRSP1 (p.R311S)
I-1,2,3,4 N/A N/A
II-1 −/− −/−
II-2,3,4,5,6,7 N/A N/A
II-8 +/− −/−
II-9 −/− +/−
II-10 −/− −/−
II-11,12,13,14 N/A N/A
III-1,2 N/A N/A
III-3,4 −/− −/−
III-5,6,7 N/A N/A
III-8 +/− +/−
III-9 −/− −/−
III-10 +/− +/−
III-11 +/− +/−
III-12 +/− +/−
on HEK293 cells transiently overexpressing both proteins. The
results showed that the mutation drastically inhibited the
CSRP1/SRF interaction by 82% (Supplementary Figure 3A). The
functional interaction was subsequently tested in co-transfection
assays which show that both CSRP1 and SRF can synergistically
activate the NPPA, VEGF, and NOS3 promoters up to 100-, 22.3-,
and 14-folds, respectively (Supplementary Figure 3B), and that
the mutation completely inhibits this synergy over the VEGF, and
NOS3 promoters while drastically inhibiting it by 50% over the
NPPA promoter (Supplementary Figures 3C,D).
CSRP1/GATA4 Interaction Altered by the
p.E154Vfs∗99 CSRP1 Variant
GATA transcription factors and LIM-domain proteins (including
CSRP1) have comparable zinc finger motifs through which they
heterodimerize (Chang et al., 2003). Thus, we assessed the effect
of the mutation by co-immunoprecipitation assay on HEK293
cells transiently expressing WT CSRP1, p.E154Vfs∗99 variant,
and GATA4, or GATA5, or GATA6. Our results show that
only GATA4 and GATA6 readily interact with CSRP1 while
GATA5 does not (Figure 4).More importantly the CSRP1 variant
dramatically inhibited the GATA4/CSRP1 interaction up to 85%
but has a mild effect on the CSRP1/GATA6 interaction which
increased by∼15% (Figures 4A,B). Concurrently, the functional
interaction between GATA4 and CSRP1 was also tested in
co-transfection assays. The synergy between the two proteins
was completely lost on the cardiac enriched promoters NPPA,
VEGF, and NOS3 promoters going down from 22-fold to 5
(Supplementary Figure 4).
FIGURE 3 | Transcriptional activity of WT and/or MUT CSRP1. (A–C) WT or MUT CSRP1 was transiently transfected along with 3.5 µg of NPPA, VEGF, and
NOS3-luciferase promoters respectively in HEK293 cells. Relative luciferase activities were presented as fold changes. The data represent the means of 3 independent
experiments done in duplicates and the values are ± SE. P-value was assessed used Students’ T-test. Significance p < 0.01 is indicated by an (**) while p < 0.05 is
indicated by (*); significance is tested relative to control. The triangle represents an increasing dose of the WT and MUT CSRP1 (200, 400, and 600 ng, respectively).
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FIGURE 4 | Selective inhibition of the GATA4 physical interaction with CSRP1 by the p.E154Vfs*99 mutation. (A–C) The amount of the proteins used for
immunoprecipitation was ten times that used in western blot. Nuclear lysates of CSRP1 protein were immunoprecipitated with anti-HA antibody and CSRP1 proteins
were detected using anti-Flag antibody (arrows). After membrane stripping, subsequent western blot analysis using anti-HA was performed to detect GATA4, 5, and 6
proteins (arrowheads).
TBX5 Is a Novel Partner for CSRP1
The T-Box transcription factor, TBX5, is involved in vertebrate
cardiac and limb development and mutation in this gene cause
amongst others cardiac septal malformation, similar to the ones
observed in our family. Moreover, it was shown that TBX5
interacts with the chicken and zebrafish LMP4, a member of
PDZ-LIM proteins (Camarata et al., 2006). Thus, we were
interested in assessing a potential interaction between CSRP1
and TBX5. Co-immunoprecipitation results revealed that TBX5
is a strong physical partner of CSRP1 (Figure 5A). Interestingly,
the results of co-immunoprecipitation assays of HEK293cells
overexpressing TBX5 and the variant revealed that the mutation
decreased the interaction by up to 55.3%. We also assessed the
functional interaction between CSRP1 and TBX5 by transient co-
transfection assays in HEK293. The results showed a synergistic
activation of these promoters reaching up to 40-fold on NOS3
promoter (Figure 5B); however, this synergy was completely
abolished by the mutation in CSRP1 (Figures 5C,D).
Exome Sequencing: A Novel TRPS1 Variant
Since we did not find variations inCSRP1 partners including SRF,
GATA4, and TBX5 to explain the genotype of the phenotypically
normal individual II.8 (Table 1), we decided to carry on whole-
exome sequencing (WES) on selected members of the family
(II.8, II.9, III.1, III.2, III.8, III.9, III.10, III.11, and III.12). The
raw data results showed an average total yield of ∼6 × 109 bp
reads, with an average throughput depth of 87. Quality control
analysis with the FastQC software showed an average of 90.6%
coverage of target regions with more than 20 reads. From a
total number of around 70,000 single nucleotide polymorphisms
(SNPs) and 6,000 insertions/deletions (Indels), we only analyzed
those occurring in the coding regions of the genes. We started
by filtering out all variants with a minor allele frequency (MAF)
>5%, and we kept common inherited variants amongst affected
individuals with the cardiac and/or polydactyly phenotype
(Supplementary Table 2). We first assumed an unbiased recessive
model of inheritance for the cardiac phenotype (Figure 1),
but we have failed to find a common recessive variant for
individuals III8-10, -12 (Figure 1). We then moved to test
the hypothesis of a common autosomal dominant variant
shared between members affected with polydactyly alone as
per the analysis of the phenotypes using the same stringent
approach (Figure 1). We did not identify any rare damaging
variant in previously documented polydactyly associated genes
(Supplementary Table 3). Furthermore, there were no single
variants common to all polydactyly affected individuals and not
found in the rest of the healthy individuals fromwithin the family
and/or in the 200 in-house Lebanese exomes. This prompted us
finally to investigate the potential implication of CNVs in both
cardiac and limb defects independently using the DeAnnCNV
webserver. The results did not yield any such significant CNV
shared among patients as compared to controls.
We then interrogated the digenic hypothetical model for CHD
inheritance in the family by identifying rare damaging variants
inherited from the mother (II.9) to the affected CHD probands.
Using this approach with yet the same filtering stringency in
addition to excluding any variant found in the in-house Lebanese
exome database, we identified a list of 54 variants (Supplementary
Table 4) amongst the individuals with cardiac defects (III-8, -9, -
12 Figure 1) that are inherited from the mother (II-9, Figure 1).
Amongst these, a non-synonymous mutation in exon 8 of the
TRPS1 gene [NM_014112.4:c.933G>C] was considered to be
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FIGURE 5 | The effect of p.E154Vfs*99 mutation on the physical and functional interaction between CSRP1 and TBX5. (A) Physical interaction between HA-tagged
TBX5 and Flag-tagged CSRP1 (WT and MUT) is demonstrated in the lanes of the right panel The amount of the proteins used for immunoprecipitation was 10 times
that used in western blot. Nuclear lysates of CSRP1 protein was immunoprecipitated with anti-HA antibody and CSRP1 proteins were detected using anti-Flag
antibody. After membrane stripping, subsequent western blot analysis using anti-HA was performed to detect TBX5 protein. (B–D) Transcriptional activity of WT
and/or MUT CSRP1 along with TBX5. WT or MUT CSRP1 were transiently cotransfected with TBX5 along with NPPA, VEGF, and NOS3-luciferase promoters
respectively in HEK293 cells. Relative luciferase activities were presented as fold changes. The data represent the means of 3 independent experiments done in
duplicates and the values are ± SE. P-value was assessed used Students’ T-test. Significance p < 0.01 is indicated by (**), while p < 0.05 is indicated by (*);
significance of synergy for WT is tested relative to the sum of individual activations, while that of mutant is tested relative to synergy The triangle represents an
increasing dose of the WT and MUT CSRP1 (400 and 600 ng, respectively) and TBX5 (200 and 400 ng).
potentially implicated in the defect because of the previously
documented expression and function of this gene in the heart,
while other variants were within coding regions of genes not
implicated in heart development and diseases. We confirmed
by Sanger sequencing the TRPS1 genotyping of all available
members of the family (Table 1). Structurally, this variation
leads to a missense p.R311S mutation (ENST00000519076) at
the level of the protein (Figures 6A–C). In silico analysis shows
that the p.R2311S variant could have a probably damaging
or neutral effect on the protein function, depending on the
software used SIFT (http://sift.jcvi.org), Polyphen2 (http://
genetics.bwh.harvard.edu/pph2/), Provean (http://provean.jcvi.
org/index.php), andMutationTaster (http://www.mutationtaster.
org). The variant is not found in the gnomAD database though
highly covered both in the exome and genome databases (AF =
0). We thus hypothesized that a combinatorial role for the two
variants in CSRP1 and TRPS1 could explain the CHD phenotype.
Role of the Digenic CSRP1/TRPS1 Variants
In order to assess the impact of the p.R311S variant on the
functional properties of TRPS1, site-directed mutagenesis was
carried out on the coding region of the human TRPS1 cDNA
sub-cloned into an HA-tagged plasmid. Both plasmids were
sequenced before transiently expressing them into Hela and
HEK293 cells. The wild type and mutated proteins were equally
produced as assessed by western blot analysis of nuclear proteins
extracted from these cells (Figure 6D). Cellular localization was
assessed inHela cells which showed that both proteins are present
in the nuclei and cytoplasm of the transfected cells with no
substantial differences (Figure 6E). Functional luciferase assays
on the three cardiac enriched promoters did not show any
significant transcriptional activity (data not shown), prompting
us to study the direct interaction between CSRP1 and TRPS1. Co-
immunoprecipitation assays from HEK293 cells overexpressing
both proteins show a relatively stable interaction between the
two (Figures 6F,G). Both mutations in CSRP1 and TRPS1 totally
inhibit the interaction with the obligate partner (Figure 6, and
data not shown), proving that both variants are deleterious.
DISCUSSION
We used both targeted exome and whole exome sequencing
to unravel the genetic factors responsible for both cardiac
malformations and polydactyly in a large Lebanese family
with high consanguinity. We showed that despite the high
consanguinity between members of the family, there were no
homozygous mutations that could account for either or both
phenotypes in the annotated genes. In addition, we found that
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FIGURE 6 | The Physical interaction between TRPS1 and CSRP1. (A)Whole-exome sequencing shows a point mutation [NM_014112.4:c.933G>C] in Trsp1 gene.
(B) Sanger sequencing of TRPS1 gene confirms the point mutation G>C in exon 8. (C) Schematic Representation of the TRPS1 protein with the different domains (Zf,
Zinc finger; NLS, Nuclear Localization Signal), and the position of the mutation. (D) Nuclear extracts from transfected HEK293 cells with either WT TRPS1 or MUT
TRPS1 were resolved on an SDS-PAGE. Immunoblotting using anti-HA antibody showed equal amounts of expressed proteins at 20 µg. Anti-GAPDH was used as a
loading control. (E) Immunofluorescence of Hela cells transfected with WT TRPS1 and MUT TRPS1 plasmids. The localization of TRPS1 was visualized using anti-HA
antibody followed by biotinylated anti-Rabbit antibody and then Streptavidin Texas Red for both WT TRPS1 and MUT TRPS1. Nuclei were stained blue with the
Hoechst 33342 dye. TRPS1 (WT or MUT) showed cytoplasmic and nuclear localization (Red color). (F) Physical interaction between HA-tagged TRPS1 and
Flag-tagged CSRP1 is demonstrated in the lanes of the right panel. The amount of the proteins used for immunoprecipitation was ten times that used in western blot.
Nuclear lysates of CSRP1 protein was immunoprecipitated with anti-HA antibody and WT CSRP1 protein was detected using anti-Flag antibody. (G) This interaction is
lost when using the MUT TRPS1 protein instead of the WT.
both phenotypes are not linked, and that the cardiac phenotype
is associated with a novel mutation in the gene encoding CSRP1.
This is the second gene encoding a LIM protein shown to
be implicated in CHD after ISL1 (Stevens et al., 2010; Luo
et al., 2014). In addition, we interrogated the penetrance of
this mutation by searching for potential modifiers. Our results
unraveled a novel di-genic interaction between CSRP1 and
TRPS1 which encodes a GATA-like zinc finger protein.
CSRP1: A Specific Integrator of
Cardiac-Enriched Transcription Factors
To the best of our knowledge, this is the first CSRP1 variant
identified in CHD patients or in any other cardiovascular
diseases. The p.E154Vfs∗99 mutation did not affect the cellular
localization of the protein; however, it affected the structure
and function of CSRP1 protein. The disruption of the protein
physical interactions with its partners and the inhibition of the
transcriptional activity on several cardiac enriched promoters
suggest the severity of this mutation which affects the cardiac
phenotypic outcome in the family. Our in silico analysis
showed that this mutation is disrupting the second LIM
domain at the C-terminal of the protein. The LIM domain has
been shown to be implicated in protein-protein interactions
(Arber et al., 1994; Schmeichel and Beckerle, 1994). Since
the mutation lies in an essential domain of the protein, we
suggested a conformational, structural and functional change
at the protein level. This was corroborated by the obstruction
of the physical interaction between CSRP1 and its partner
SRF, a transcription factor mandatory for the appearance of
cardiac mesoderm during embryonic mouse development and
an essential partner of cardiac GATA4 (Wang et al., 2002; Small
and Krieg, 2003). Similarly, the p.E154Vfs∗99 has abrogated the
interaction between CSRP1 and GATA4 which is also a vital
transcription factor in the early and late heart development such
as valve formation and cardiac septation (Molkentin et al., 1997).
Dominant GATA4 mutations cause severe CHD including atrial
and atrioventricular septal defects (ASDs and AVSDs) as well
as Tetralogy of Fallot (Garg et al., 2003; Nemer et al., 2006).
This role of GATA4 in multiple forms of CHD is reminiscent
of our findings for CSRP1 in this particular family, and could
be explained by the broad yet timely expression pattern of the
proteins during heart development. Indeed, we showed that
Frontiers in Genetics | www.frontiersin.org 10 December 2017 | Volume 8 | Article 217
Kamar et al. CSRP1 and Congenital Heart Disease
CSRP1 is expressed in all cardiac compartments, and it was
previously shown that a Cre-driven CSRP1 enhancer is highly
expressed in the outflow tract, and both in the mesenchymal
cells as well as cardiomyocytes supporting a role for CSRP1 in
cardiac development (Snider et al., 2008). This specific expression
in the heart would support a potential role for the CSRP1
variant in the different cardiac phenotypes observed in our
family, but the fact that one normal individual carrying it
stands against this conclusion. Interestingly, we showed that the
mutation in CSRP1 did not affect its interaction with GATA5
and/or GATA6 suggesting different interfaces with different
outcomes on different promoters. Additionally, we documented
a novel interaction of CSRP1 with TBX5, a member of the
T-box family, implicated in the Holt-Oram syndrome. This
interaction is not novel between the two classes of protein,
since it was previously shown that the LIM4 and pdlim7
proteins regulate cellular localization of TBX5 during pectoral
and heart development (Camarata et al., 2006, 2010a,b). In our
case, the interaction is functional between the two proteins
resulting in a synergistical activation of downstream target
genes like NPPA. Although our results show that CSRP1 can
coordinate protein partners through its LIM domain to form a
robust network of transcriptional activators, it is still possible
to speculate over the contribution of the LIM DNA binding-
domain on its own on specific promoters (Kadrmas and Beckerle,
2004).
Despite the potential link that this interaction could suggest
over the polydactyly phenotype observed in members of the
family, the mutation in CSRP1 does not segregate with the
limb phenotype, and thus we exclude any role for this mutation
in the limb defects. This dichotomy in the genetic inheritance
of two different phenotypes is not however novel in the case
of CHD and limb defects. In fact, besides syndromic cases
caused by monogenic mutations like TBX1,3 and 5, SALL4,
and EVC, there are no published studies on variants that cause
only cardiac and limb defects whether monogenic or multigenic
(Kohlhase et al., 2002; Packham and Brook, 2003; Hills et al.,
2011).
CSRP1/TRPS1: A New Digenic Paradigm in
CHD
Since CHD is a multifactorial disease in that it frequently
reveals variable penetrance, genetic heterogeneity, and variable
expressivity, it was essential to unravel other partners for CSRP1
that could account for the partial penetrance problem we faced
in this particular family. Since the CSRP1 variant is inherited
from the father’s side (II-8) who yet has a normal cardiac
phenotype but has a limb defect, it was instrumental to go
for whole-exome sequencing since cardiac targeted sequencing
was not enough to explain the cardiac phenotypes in probands
and we could not find a variation that explains the limb
phenotype. The extracted data failed to show any monoallelic
variation in genes previously shown to be linked to polydactyly
(Biesecker, 2011) nor to yield a common variant between the 7
members with the same phenotype included in the screening.
In contrast, the WES data yielded multiple variants inherited
from the mother (II-9) and only present in the cardiac-affected
probands. The TRPS1 variant (p.R311S) stands alone among a
short list of missense variants (Supplementary Table 4), since
it was novel, absent from the gnomad database, as well from
200 Lebanese exomes. In addition both the TRPS1 and CSRP1
variants were absent from regional databases like the Saudi
Genome project, reinforcing again the claim that both are
responsible for the cardiac phenotype. Genetically, besides the
TRPS1 variant, only a SNV in SHOX2 (Supplementary Table 4)
could have had a deleterious effect on cardiac development, but
the fact that SHOX2 is exclusively expressed in the sinoatrial
node makes it less plausible in this particular familial case
(Puskaric et al., 2010; Hoffmann et al., 2016). The in silico
analysis shows that this variant would have a moderate effect
on the function of the protein, and we thus hypothesized that
alone it would not affect cardiac development, thus explaining
the normal phenotype of the mother. Since probands III-8, -10,
and -12 who carry the CSRP1 and TRPS1 variants expressed
a cardiac phenotype, we hypothesized that the TRPS1 variant
has no effect unless it is expressed with the CSRP1 variant.
Mutations or deletions in TRPS1 give rise to Tricho-rhino-
phalangeal syndrome (TRPS), and a relatively high proportion
of patients with TRPS exhibit CHD, ranging from minor to
severe anomalies (Verheij et al., 2009; Maas et al., 2015).
Although previous reports did not describe Trps1 expression
in the mammalian heart, Trps1 was recently shown to be
expressed in a restricted region within the cardiac cushion of
OFT and developing valves (Nomir et al., 2016). This could
partially explain why patients with TRPS1 mutations show a
broad range of congenital cardiac defects. In our case, we
establish a direct physical interaction between the two proteins
that was affected by the CSRP1 variant. However, we suspect a
much more complicated functional regulation since TRPS1 acts
as a repressor and CSRP1 as a weak activator of downstream
target genes. We hypothesize that the transcriptomal assembly
of CSRP1 and TRPS1 co-factors over cardiac promoters, would
be largely affected by the mutations, and cause the observed
phenotypes in the family members along the broad spectrum
of phenotypes associated to CHD. We also suggest that the
inhibitory role of TRPS1 over the GATA-driven promoters is
at stake in this interaction, and that the mutation in CSRP1
would specifically affect GATA4 transcriptional activation in a
context where both TRPS1 and GATA4/5/6 are competing for
DNA occupancy.
Although efficient strategies such as whole exome sequencing
potentially contribute to the understanding of rare human
diseases and allows the detection of multiple rare variants, they
are still short of elucidating the network of such genes that
are involved in CHD (Postma et al., 2016). Thus, genome-
wide association studies (GWAS) should be combined with
WES or even WGS since they have provided evidence that
common genetic variation can influence the risk of certain
types of CHD (detect somatic mutations and noncoding
sequences). Many whole-genome CNV screening studies indeed
have revealed that a significant number of CHD patients have
pathogenic CNVs. The highest frequency of pathogenic CNVs
are found in patients who have both CHD and extra-cardiac
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anomalies which is similar to our case (Andersen et al.,
2014).
CONCLUSION
Dissecting phenotypes and establishing direct
genotype/phenotype interaction is a must in any strategical
approach in CHD. We have shown that despite the high
consanguinity within one family, there are no homozygous
mutations that could explain the associated cardiac and limb
defects. In contrast, a digenic model of inheritance is proposed
to explain the cardiac phenotype.
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